Skip to main content
. 2021 Jun 26;13(7):1244. doi: 10.3390/v13071244

Table 2.

Clinical sensitivity according to the time post symptom onset.

Overall Sensitivity
N, % (95% CI)
D 0–5
N, % (95% CI)
D 6–10
% (95% CI)
D 11–15
% (95% CI)
D 16–20
% (95% CI)
D 21–30
% (95% CI)
D 31–90
% (95% CI)
D ≥ 91
% (95% CI)
Specificity
% (95% CI)
Sample No. 528 56 89 90 77 62 114 40 161
CMIA (Abbott)
IgM antiS 394
74.6
(70.6–78.2)
13
23.2
(12.9–36.4)
54
60.6
(49.7–70.8)
83
92.2
(84.6–96.8)
74
96.1
(89–99.1)
57
91.9
(82.1–97.3)
89
78
(69.3–85.2)
24
60
(43.3–75.1)
2
98,7
(95.5–99.8)
IgG antiNP 372
70.4
(66.3–74.3)
8
14.2
(6.3–26.2)
27
30.3
(21–40.9)
72
80
(70.2–87.6)
72
93.5
(85.4–97.8)
57
91.9
(82,1–97.3)
103
90.3
(83.3–95)
33
82.5
(67.2–92.6)
2
98,7
(95.5–99.8)
IgM/IgG * 437
82.7
(79.2–85.8)
13
23.2
(12.9–36.4)
56
62.9
(52–72.9)
86
95.5
(89–98.7)
75
97.4
(90.9–99.6)
60
96.7
(88.8–99.6)
111
97.3
(92.5–99.4)
36
90
(76.3–97.2)
4
97.5
(93.7–99.3)
ELISA (Epitope)
IgM antiNP 149
28.2
(24.4–32.2)
6
10.7
(4–21.8)
21
23.5
(15.2–33.7)
51
56.6
(45.8–67)
31
40.2
(29.2–52)
25
40.3
(28.5–53.5)
13
11.4
(6.21–18.87)
2
5
(0.6–16.9)
4
97.5
(93.7–99.3)
IgG antiNP 343
64.9
(60.7–69)
10
17.8
(8.9–30.4)
31
34.8
(25–45.6)
68
75.5
(65.3–84)
65
81.8
(71.3–89.6)
54
85.4
(74.2–93.1)
90
78
(69.3–85.2)
25
60
(43.3–75.1)
3
98.1
(94.6–99.6)
IgM/IgG * 359
68
(63.8–72)
10
17.9
(8.9–30.4)
33
37.1
(27.1–48)
73
81.1
(71.5–88.6)
66
85.7
(75.9–93)
58
93.5
(84.3–98.2)
92
80.7
(72.2–87.5)
27
67.5
(50.9–81.4)
5
96.2
(92–98.6)
Sample No. 559 56 89 90 77 62 114 71 161
CLIA IgG antiS1/S2 DiaSorin 390
69.8
(65.7–73.5)
6
10.7
(4–21.8)
22
24.7
(16.1–35)
64
71.1
(60.6–80.1)
68
88.3
(78.9–94.5)
54
87
(76.1–94.2)
107
93.8
(87.7–97.5)
69
97.2
(83–99.3)
2
98.7
(95.5–99.8)
Sample No. 559 56 89 90 77 62 114 71 158
ECLIA total antiNP Roche 403
70.4
(66.3–74.3)
7
12.5
(5.1–24)
29
32.5
(23–43.3)
64
71.1
(60.6–80.1)
68
88.3
(78.9–94.5)
54
87
(76.1–94.2)
110
96.4
(91.2–99)
71
100
(91.1–100)
0
100
(97.7–100)

* Positive if either IgM or IgG is positive.